Netarsudil-associated epithelial keratopathy

• Published in: American journal of ophthalmology case reports Vol. 19; p. 100800
• Main Authors: Ramakrishnan, Meera S, Addis, Victoria M, Lehman, Amanda Y, Sankar, Prithvi S
• Format: Report
• Language: English
• Published: 01.09.2020
• ISSN: 2451-9936
• DOI: 10.1016/j.ajoc.2020.100800

PURPOSETo report 2 cases with a novel finding of bullous epithelial keratopathy associated with netarsudil use. OBSERVATIONSA 72-year-old man with history of primary open angle glaucoma was started on netarsudil daily in both eyes for uncontrolled intraocular pressures despite treatment with latanoprost, brimonidine, and dorzolamide-timolol. One month later he presented with bilateral conjunctival hyperemia, predominantly inferior corneal epithelial bullae, and keratic precipitates without hypopyon. Netarsudil was discontinued, and the patient was started on topical steroids. One week later, the hyperemia and corneal edema had resolved while many small keratic precipitates persisted.A 29-year-old man with history of rubella-associated glaucoma and chronic postoperative inflammation on prednisolone was started on netarsudil in his left eye only for elevated intraocular pressures despite latanoprost, brimonidine, and dorzolamide-timolol. Two months later, he complained of eye pain and decreased vision since starting netarsudil. Examination revealed mild hyperemia and inferior corneal epithelial bullae without keratic precipitates. Netarsudil was discontinued, and two weeks later, conjunctival injection resolved and cornea cleared. CONCLUSIONS AND IMPORTANCENetarsudil ophthalmic solution 0.02% (Rhopressa) is a rho-kinase inhibitor recently approved for lowering intraocular pressure in open-angle glaucoma or ocular hypertension. As netarsudil continues to be increasingly used, physicians and patients need to be aware of this new possible adverse effect.